Guanidinoacetate Methyltransferase Deficiency: A Review of Guanidinoacetate Neurotoxicity

Abstract Guanidinoacetate methyltransferase (GAMT) deficiency is an autosomal recessively inherited disorder of the metabolism of creatine that leads to depleted levels of creatine and excessive concentrations of guanidinoacetate (GAA). Patients affected develop neurological symptoms during childhood, such as muscular hypotonia, involuntary extrapyramidal movements, convulsions, slurred speech, and even autism. Although the pathophysiology of GAMT deficiency is unclear, neurological dysfunction is commonly found in this disease, and it has been mainly attributed to a reduction in creatine or/and an increase in GAA levels. Reports from literature suggest that GAA may interfere with neuronal γ-aminobutyric acid (GABA) receptors type A and cause epilepsy in human. Preclinical studies show that GAA increases free radical formation and decreases brain antioxidant defenses, inducing alteration in oxidative status. Guanidinoacetate also impairs energy metabolism in brain. The discussion of this review focuses on various and latest studies addressing GAMT deficiency and creatine metabolism, as well as addresses the question of neurotoxicity GAA.

Saved in:
Bibliographic Details
Main Authors: Marques,Eduardo P., Wyse,Angela T. S.
Format: Digital revista
Language:English
Published: Latin American Society Inborn Errors and Neonatal Screening (SLEIMPN); Instituto Genética para Todos (IGPT) 2016
Online Access:http://old.scielo.br/scielo.php?script=sci_arttext&pid=S2326-45942016000100403
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S2326-45942016000100403
record_format ojs
spelling oai:scielo:S2326-459420160001004032019-05-28Guanidinoacetate Methyltransferase Deficiency: A Review of Guanidinoacetate NeurotoxicityMarques,Eduardo P.Wyse,Angela T. S. guanidinoacetate methyltransferase deficiency creatine guanidinoacetate neurotoxicity Abstract Guanidinoacetate methyltransferase (GAMT) deficiency is an autosomal recessively inherited disorder of the metabolism of creatine that leads to depleted levels of creatine and excessive concentrations of guanidinoacetate (GAA). Patients affected develop neurological symptoms during childhood, such as muscular hypotonia, involuntary extrapyramidal movements, convulsions, slurred speech, and even autism. Although the pathophysiology of GAMT deficiency is unclear, neurological dysfunction is commonly found in this disease, and it has been mainly attributed to a reduction in creatine or/and an increase in GAA levels. Reports from literature suggest that GAA may interfere with neuronal γ-aminobutyric acid (GABA) receptors type A and cause epilepsy in human. Preclinical studies show that GAA increases free radical formation and decreases brain antioxidant defenses, inducing alteration in oxidative status. Guanidinoacetate also impairs energy metabolism in brain. The discussion of this review focuses on various and latest studies addressing GAMT deficiency and creatine metabolism, as well as addresses the question of neurotoxicity GAA.info:eu-repo/semantics/openAccessLatin American Society Inborn Errors and Neonatal Screening (SLEIMPN); Instituto Genética para Todos (IGPT)Journal of Inborn Errors of Metabolism and Screening v.4 20162016-01-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S2326-45942016000100403en10.1177/2326409816669371
institution SCIELO
collection OJS
country Brasil
countrycode BR
component Revista
access En linea
databasecode rev-scielo-br
tag revista
region America del Sur
libraryname SciELO
language English
format Digital
author Marques,Eduardo P.
Wyse,Angela T. S.
spellingShingle Marques,Eduardo P.
Wyse,Angela T. S.
Guanidinoacetate Methyltransferase Deficiency: A Review of Guanidinoacetate Neurotoxicity
author_facet Marques,Eduardo P.
Wyse,Angela T. S.
author_sort Marques,Eduardo P.
title Guanidinoacetate Methyltransferase Deficiency: A Review of Guanidinoacetate Neurotoxicity
title_short Guanidinoacetate Methyltransferase Deficiency: A Review of Guanidinoacetate Neurotoxicity
title_full Guanidinoacetate Methyltransferase Deficiency: A Review of Guanidinoacetate Neurotoxicity
title_fullStr Guanidinoacetate Methyltransferase Deficiency: A Review of Guanidinoacetate Neurotoxicity
title_full_unstemmed Guanidinoacetate Methyltransferase Deficiency: A Review of Guanidinoacetate Neurotoxicity
title_sort guanidinoacetate methyltransferase deficiency: a review of guanidinoacetate neurotoxicity
description Abstract Guanidinoacetate methyltransferase (GAMT) deficiency is an autosomal recessively inherited disorder of the metabolism of creatine that leads to depleted levels of creatine and excessive concentrations of guanidinoacetate (GAA). Patients affected develop neurological symptoms during childhood, such as muscular hypotonia, involuntary extrapyramidal movements, convulsions, slurred speech, and even autism. Although the pathophysiology of GAMT deficiency is unclear, neurological dysfunction is commonly found in this disease, and it has been mainly attributed to a reduction in creatine or/and an increase in GAA levels. Reports from literature suggest that GAA may interfere with neuronal γ-aminobutyric acid (GABA) receptors type A and cause epilepsy in human. Preclinical studies show that GAA increases free radical formation and decreases brain antioxidant defenses, inducing alteration in oxidative status. Guanidinoacetate also impairs energy metabolism in brain. The discussion of this review focuses on various and latest studies addressing GAMT deficiency and creatine metabolism, as well as addresses the question of neurotoxicity GAA.
publisher Latin American Society Inborn Errors and Neonatal Screening (SLEIMPN); Instituto Genética para Todos (IGPT)
publishDate 2016
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S2326-45942016000100403
work_keys_str_mv AT marqueseduardop guanidinoacetatemethyltransferasedeficiencyareviewofguanidinoacetateneurotoxicity
AT wyseangelats guanidinoacetatemethyltransferasedeficiencyareviewofguanidinoacetateneurotoxicity
_version_ 1756441178990968832